Glycogen-Based Cationic Polymers for Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral gene vectors for nucleic acid delivery, such as cationic polymers, face challenges including toxicity, limited transfection efficacy, and instability due to interactions with anionic biological structures, leading to rapid degradation and poor cellular uptake.
Innovation Solution
Development of novel glycogen-based cationic polymers with specific amine groups and pKa values, which form stable complexes with anionic compounds, reducing toxicity and enhancing cellular uptake by controlling osmolarity and pH-dependent release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic polymers are used for nucleic acid delivery, then transfection efficiency is improved, but toxicity increases due to interactions with anionic biological structures
Solution Approach 1:
The patent modifies the chemical parameters of the polymer by introducing amino groups with specific pKa values (6.5-7.5 and 8.5-9.5) at controlled proportions. This parameter optimization allows the polymer to maintain sufficient positive charge for nucleic acid binding while reducing excessive interactions with anionic biological structures, thereby lowering toxicity while preserving transfection efficiency
Solution Approach 2:
The patent creates a composite polymer structure combining glycogen backbone with specific amino group substituents. This composite design integrates the biocompatibility of glycogen with the cationic properties of amino groups, achieving a balance between transfection capability and reduced toxicity toward cellular components
2Productivity
If cationic polymers are used for nucleic acid complexation, then delivery capability is improved, but stability decreases due to rapid degradation by cationic enzymes
Solution Approach 1:
The patent optimizes the proportion of amino groups with different pKa values to create an optimal charge density. This parameter control reduces the polymer's susceptibility to cationic enzymes (nucleases and proteases) while maintaining sufficient binding affinity for nucleic acids, achieving both stable circulation and effective delivery
Solution Approach 2:
The patent uses the amino groups as intermediary structures that mediate between the nucleic acid payload and the biological environment. These groups provide controlled electrostatic interactions that protect the nucleic acid from enzymatic degradation while facilitating cellular uptake, acting as a protective intermediary layer
3Productivity
If cationic polymers are used for cellular uptake enhancement, then transfection is improved, but aggregation occurs leading to poor solubility
Solution Approach 1:
The patent carefully controls the proportion and types of amino groups to optimize the hydrophilicity-hydrophobicity balance. This parameter adjustment prevents excessive aggregation by controlling intermolecular interactions, maintaining solubility while preserving the cationic charge necessary for cellular uptake enhancement
Solution Approach 2:
The patent introduces different amino group substituents with varying local properties (hydrophilic, hydrophobic, charged) at specific positions on the polymer chain. This local quality differentiation creates steric and electrostatic repulsion that prevents aggregation while maintaining overall solubility and cellular interaction capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The glycogen-based cationic polymers demonstrate low cytotoxicity, efficient delivery of anionic compounds to specific targets, and stability in solution, forming nanometric complexes that facilitate transfection without aggregation, thereby overcoming the limitations of existing vectors.
Implementation Method 1
Typically, the interactions that are formed between the delivering system and the active principle are non-covalent, for example electrostatic, ionic or van der Waals interactions, hydrogen bonding and the like.
Implementation Method 2
Polymers with buffer capacity inhibit the activity of the lysosomal nucleases and, at the same time, alter the osmolarity of the endosomes. While the polymers are sequestering H+ ions, the osmolarity of the endosomes increases, water penetrates into the endosomes and their volume increases, which may lead to their rupture and the release of the complex into the cytoplasm.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to glycogen-based cationic polymers, to complexes of the said cationic polymers with anionic compounds, to pharmaceutical compositions comprising the said complexes, and to the use of the said complexes for delivering or transfecting the said anionic compounds to a specific pharmacological target, such as, for instance an organ, a tissue or a cell.